Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (3)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07534280Not ApplicableCompletedPrimary

Herbal Tea Extract for Management of Rhinosinusitis

NCT05984004Not ApplicableCompletedPrimary

Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans

NCT03068728Not ApplicableCompletedPrimary

Analysis of Hemostatic Agents Compared to Physiologic Hemostasis

Showing all 3 trials

Research Network

Activity Timeline